Paying users zone. Data is covered by 
.
Get 1 month access to Merck & Co. Inc. for $19.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Merck & Co. Inc. (MRK)
Long-term (Investment) Activity Analysis
Difficulty: Beginner
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Ratios (Summary)
Merck & Co. Inc., long-term (investment) activity ratios
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Net fixed asset turnover | |
|
|
|
|
|
| Total asset turnover | |
|
|
|
|
|
| Equity turnover | |
|
|
|
|
Based on: 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-28), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-27).
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Merck & Co. Inc.’s net fixed asset turnover deteriorated from 2016 to 2017 and from 2017 to 2018. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Merck & Co. Inc.’s total asset turnover improved from 2016 to 2017 and from 2017 to 2018. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Merck & Co. Inc.’s equity turnover improved from 2016 to 2017 and from 2017 to 2018. |
Net Fixed Asset Turnover
Merck & Co. Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Sales | |
|
|
|
|
|
| Property, plant and equipment, at cost, net of accumulated depreciation | |
|
|
|
|
|
| Ratio | ||||||
| Net fixed asset turnover1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-28), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Net fixed asset turnover = Sales ÷ Property, plant and equipment, at cost, net of accumulated depreciation
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Merck & Co. Inc.’s net fixed asset turnover deteriorated from 2016 to 2017 and from 2017 to 2018. |
Total Asset Turnover
Merck & Co. Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Sales | |
|
|
|
|
|
| Total assets | |
|
|
|
|
|
| Ratio | ||||||
| Total asset turnover1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Total Asset Turnover, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-28), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Total asset turnover = Sales ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Merck & Co. Inc.’s total asset turnover improved from 2016 to 2017 and from 2017 to 2018. |
Equity Turnover
Merck & Co. Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (USD $ in millions) | ||||||
| Sales | |
|
|
|
|
|
| Total Merck & Co., Inc. stockholders’ equity | |
|
|
|
|
|
| Ratio | ||||||
| Equity turnover1 | |
|
|
|
|
|
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| Abbott Laboratories | |
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
| Biogen Inc. | |
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
| Equity Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | |
|
|
|
|
|
| Equity Turnover, Industry | ||||||
| Health Care | |
|
|
|
|
|
Based on: 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-28), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-27).
1 2018 Calculation
Equity turnover = Sales ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Merck & Co. Inc.’s equity turnover improved from 2016 to 2017 and from 2017 to 2018. |